Chemotherapy with alvenor for rectal cancer with high YWHAB
Part of Cancer, Digestive system clinical trials.
This trial tests adding the drug alvenor to standard chemotherapy before surgery for rectal cancer patients whose tumors have high levels of a protein called YWHAB. The goal is to see if this combination can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (a type of rectal cancer) that has not spread to other parts of the body.
- Your tumor has high levels of the YWHAB protein (a lab test will check this).
- You have not had any previous chemotherapy or other cancer treatments for your rectal cancer.
- You are between 18 and 75 years old and in good overall health (able to perform daily activities).
- You have adequate kidney, liver, and blood cell function (confirmed by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
This trial tests whether combining an immunotherapy drug (PD-1 inhibitor) with intense chemotherapy before surgery works better than standard chemotherapy alone for a certain type of locally advanced rectal cancer. It is for people whose tumors have normal DNA repair (pMMR) and are very low in the rectum.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.